CymaBay Therapeutics (NasdaqCM: CBAY) is a clinical stage biopharmaceutical company developing therapies for metabolic and orphan diseases. The Company’s lead product candidate is arhalofenate, an anti-flare and serum uric acid (sUA) lowering drug for the treatment of gout. Initial signs of efficacy have been shown in several Phase II trials. A pivotal Phase III program is expected to launch in the first half of 2016 pending partnership discussions. The Company’s is also developing MBX-8025 for the treatment of homozygous familial hypercholesterolemia (HoFH) and primary biliary cirrhosis (PBC). Results from a Phase II study in HoFH are expected in the fourth quarter of 2015 and CymaBay expects to initiate a Phase II study in PBC in the fourth quarter of 2015.